Drug intelligence / Profile preview

FOLFOXIRI + PD-1 inhibitor

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

FOLFOXIRI + PD-1 inhibitor is a combination therapy regimen that combines the intensive triple chemotherapy protocol FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) with immune checkpoint inhibition through a PD-1 inhibitor. FOLFOXIRI targets DNA synthesis and repair through multiple mechanisms, while PD-1 inhibitors enhance T cell-mediated anti-tumor immune responses by blocking the interaction between PD-1 receptors on T cells and their ligands.

Targets

TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)DNAPDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on FOLFOXIRI + PD-1 inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FOLFOXIRI + PD-1 inhibitor.

Explore the full profile